Cancer
AZ’s MedImmune signs $200m immuno-oncology partnership with Compugen
April 3, 2018Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Cancer, MedImmune, compugen, immunotherapy, oncology, pharma
AstraZeneca’s biologic R&D unit MedImmune is set to enter a partnership with Israeli drug firm Compugen to develop bi-specific and …
Top Ten most popular articles on Pharmafile.com this week
March 29, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ablynx, Cancer, GSK, Hemlibra, MSD, Roche, Sun Pharma, Takeda, brexit, pharma, tecentriq, top ten
As we approach the Easter weekend, we at Pharmafocus hope all of our readers have a great long weekend, if …
InSight Innovations to buy CureTech in $550m deal
March 28, 2018Research and Development, Sales and Marketing Cancer, CureTech, Insight Innovations, Pfizer, Teva, brain cancer, brain tumour, immunotherapy, israel
Israeli drug firm CureTech is be sold for the third time in four years, this time to InSight Innovations in …
Lifestyle factors to blame for 38% of cancers
March 23, 2018Medical Communications Cancer, Cancer Research UK, UK government, biotech, drugs, pharma, pharmaceutical
A new study by Cancer Research UK has found that more than 135,500 cases of cancer every year in the …
Convert secures €13.6m grant to develop targeted chemo for oxygen-deprived tumours
March 9, 2018Medical Communications, Research and Development Belgium, Cancer, Convert pharma, chemotherapy, pharma
Belgium’s Convert Pharmaceuticals has secured a €13.6 million grant for initial development efforts on a new targeted chemotherapy drug which …
Ontruzant launches to become first Herceptin biosimilar available in the UK
March 8, 2018Sales and Marketing Cancer, Herceptin, MSD, Ontruzant, Roche, Samsung Bioepis, pharma
Ontruzant, the biosimilar version of Herceptin (trastuzumab ) originally developed by Korean firm Samsung Bioepis, has launched for patients in …
Eisai and MSD team up to combine Lenvima and Keytruda in cancer
March 8, 2018Sales and Marketing Cancer, Eisai, Kidney cancer, Lenvima, MSD, Merck, keytruda, pharma
Pharma heavyweights MSD (Merck) and Eisai have announced they are to join forces to develop and commercialise the latter’s tyrosine …
FDA authorises first direct-to-consumer test for BRCA mutations, with caveats
March 6, 2018Research and Development, Sales and Marketing 23andME, BRCA, Cancer, FDA, breast cancer, ovarian cancer, pharma
The FDA has given its authorisation to the first ever direct-to-consumer (DTC) test to identify three BRCA gene mutations which …
Blood test could predict treatment effectiveness months earlier in breast cancer
March 6, 2018Manufacturing and Production, Research and Development Cancer, ICR, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, breast cancer, palbociclib, pharma
A team of scientists at The Institute of Cancer Research in London and The Royal Marsden NHS Foundation Trust have …
Celgene strikes $101m partnership in oncology, neurodegenerative and inflammatory
March 5, 2018Research and Development, Sales and Marketing Cancer, Celgene, Vividion, inflammatory, neurodegenerative, oncology, pharma
Celgene has inked a new multi-year partnership with biotech firm Vividion Therapeutics to leverage the latter’s proteomics and chemistry platforms …
NHS trials “world-leading” initiative to cut prostate cancer diagnoses to just days
March 5, 2018Research and Development, Sales and Marketing Cancer, MRI, NHS, pharma, prostate cancer
The NHS has revealed plans to cut the average diagnosis times for prostate cancer from six weeks to less than …
FDA expands indication of Lilly’s Verzenio in advanced breast cancer
February 27, 2018Manufacturing and Production, Sales and Marketing Cancer, Eli Lilly, FDA, Verzenio, breast cancer, pharma
Eli Lilly is celebrating the news that its cyclin-dependent kinase (CDK) 4 & 6 inhibitor Verzenio (ademaciclib) has received approval …
NICE rejects Eisai’s Halaven in earlier setting for metastatic breast cancer
February 22, 2018Sales and Marketing Brest cancer, Cancer, Eisai, Halaven, NICE, pharma
NICE has published its decision not to recommend Eisai’s Halaven (eribulin) in the treatment of locally advanced or metastatic breast …
MSD poised to acquire viral immuno-oncology firm Viralytics for $394m
February 21, 2018Research and Development, Sales and Marketing Cancer, MSD, Merck, Viralytics, acquisition, keytruda, oncology, pharma
MSD, known as Merck in the US, has announced it is to buy Australian viral immuno-oncology firm Viralytics for $394 …
NICE recommends thyroid cancer drug trio for NHS use
February 20, 2018Manufacturing and Production, Sales and Marketing Bayer, Cancer, Cometriq, Eisai, Lenvima, NICE, Nexavar, ipsen, pharma, thyroid cancer
NICE has announced its decision to recommend that three separate treatments for thyroid cancer should be made available for use …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
